A5052693890- Venous Thromboembolism Diagnosis and Management
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Central Venous Catheters and Hemodialysis
- Gastric Cancer Management and Outcomes
- Atrial Fibrillation Management and Outcomes
- Cardiac tumors and thrombi
- Thyroid Cancer Diagnosis and Treatment
- Head and Neck Cancer Studies
- Lung Cancer Treatments and Mutations
- Advanced Proteomics Techniques and Applications
- Cancer Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- COVID-19 and healthcare impacts
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Pain Management and Opioid Use
- Pancreatic and Hepatic Oncology Research
- Advanced Biosensing Techniques and Applications
- Hepatocellular Carcinoma Treatment and Prognosis
- Pain Mechanisms and Treatments
- Prostate Cancer Treatment and Research
- Mass Spectrometry Techniques and Applications
- Acute Myocardial Infarction Research
- Pediatric Pain Management Techniques
Spanish Society of Hematology and Hemotherapy
2023-2024
Hospital Universitario de Móstoles
2015-2024
Hospital General Universitario Gregorio Marañón
2003-2024
Background Axitinib, an antiangiogenic multikinase inhibitor (MKI), was evaluated in the compassionate use programme (CUP) Spain (October 2012–November 2014). Subjects and Methods 47 patients with advanced radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC, n = 34) or medullary (MTC, 13) documented disease progression were treated axitinib 5 mg b.i.d. The primary efficacy endpoint objective response rate (ORR) by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1....
Thrombosis may be included in the profile of side effects associated with CDK4/6 inhibitors. Its significance might greater than reported randomized clinical trials. To investigate this, a retrospective, multicenter study was conducted. The primary objective to calculate incidence thrombosis Secondary objectives examining impact on survival and identifying predictor variables for development venous thromboembolism (VTE) or arterial (AT). A total 986 patients were recruited. VTE/AT inhibitor...
Pancreatic carcinoma is one of the tumors associated with a higher risk for thromboembolic events, incidence rates ranging from 5% to 41% in previous retrospective series.We conducted study eleven Spanish hospitals that included 666 patients diagnosed pancreatic (any stage) between 2008 and 2011 treated chemotherapy. The main objective was evaluate venous events (VTE) this population, as well potential factors thrombosis. impact VTE on mortality also assessed.With median follow-up 9.3...
Both venous and arterial thrombotic events (VTE/AT) can be associated with Immune Checkpoint Inhibitors (ICI). However, there is a paucity of information apropos patients in routine clinical practice.
e24123 Background: The risk factors for bleeding during anticoagulation in patients with cancer-associated thrombosis (CAT) remain largely unexplored. recently developed PredictAI model ( Muñoz Martín AJ et al. JCO 40, e18744-e18744(2022) was aimed to predict major (MB) anticoagulant-treated cancer within the first 6 months following venous thromboembolism (VTE) diagnosis. goal validate using an independent cohort of from TESEO international, observational, prospective registry. Methods:...
Both venous and arterial thrombotic events (VTE/AT) can be associated with immune checkpoint inhibitors (ICI). However, there is a paucity of information apropos patients in routine clinical practice.Retrospective, multicenter study promoted by the Thrombosis Cancer Section Spanish Society Medical Oncology (SEOM). Individuals kidney or bladder cancer who initiated ICI between 01/01/2015 12/31/2020 were recruited. Minimum follow-up was 6 months (except cases demise). The primary objective to...
6027 Background: Multikinase inhibitors (MKI) have demonstrated significant activity in advanced thyroid cancer. Axitinib is a potent oral MKI targeting the three known receptors of VEGF. Methods: Patients (pts) with RAI-refractory DTC or unresectable MTC documented disease progression were included compassionate use program axitinib 5 mg bid. Primary end point was response rate (RR) by RECIST, and secondary objectives progression-free survival (PFS), toxicity profile biomarker correlation...
e20658 Background: Splanchnic vein thrombosis (SVT) is a common complication in exocrine pancreatic cancer (EPC) receiving chemotherapy ambulatory setting. However it´s true incidence and prognosis remains uncertain. So far, only few studies have addressed the outcome of patients with EPC SVT. Methods: We performed retrospective chart review to determine SVT attended ten hospitals Cancer & Thrombosis Working Group Spanish Society Medical Oncology (SEOM). 626 consecutive who were diagnosed...
BackgroundCatheter-related thrombosis (CRT) is the most frequent non-infectious complication regarding central venous access devices (CVAD). Its incidence has been reported between 13% and 66% in symptomatic asymptomatic patients, respectively, with several factors influencing its development.MethodsCRT events recorded TESEO, an international, multicentric, prospective cancer-associated registry were assessed. Descriptive association analysis for rethrombosis bleeding location of...
Triple negative breast cancer accounts for 15%-20% of all carcinomas and is clinically characterized by an aggressive phenotype poor prognosis. tumors do not benefit from targeted therapies, so further characterization needed to define subgroups with potential therapeutic value. In this work, the proteomes 125 formalin-fixed paraffin-embedded samples patients diagnosed non-metastatic triple were analyzed using data-independent acquisition + in a LTQ-Orbitrap Fusion Lumos mass spectrometer...
Patients with cancer present a higher risk of rethrombosis and bleeding secondary to anticoagulant treatment than individuals without cancer. Given the lack specific clinical trials, decision regarding optimal duration must consider multiple factors, including sex. The current study used data from international, prospective TESEO Registry that includes consecutive patients diagnosed cancer-associated thrombosis (CAT). Between July 2018 December 2022, 2,823 were included in Registry, 1,351...
Abstract Background Venous thromboembolism (VTE) is one of the leading causes death in patients with cancer. Currently, there a need to develop an easily applicable risk model that can identify who will benefit from receiving primary thromboprophylaxis reduce incidence VTE. Patients and methods This was non-interventional, multicenter, observational, prospective study carried out 62 Oncology Hematology services Spain Portugal between January 2018 December 2019. The main objective CARTAGO...
440 Background: The incidence of pancreatic cancer is increasing in developed countries. Though FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GNP) are associated with increased toxicity addressed to a well selected population, there seems have been rapid incorporation these regimens the real world. Overall survival (OS) was 11.1 months for FFX 8.5 GNP. Survival rate at 18 m 18.6%; 24 GNP 9%. Questions arisen about external validity original trials how could impact overall since they...
862 Background: Recent data suggest resection of colorectal metastases after second-line chemotherapy offers similar overall survival (OS) benefit compared to what described in first-line. The improvement response rate with FA may increase the number patients eventually undergo resection. Methods: We performed a retrospective analysis 32 from 26 Spanish hospitals who underwent surgical ORF-CRC real-life setting. Our aim was analyze impact different organs (liver, lung, etc.) terms OS and...
e13056 Background: VTE is a common complication in HGG; however, it´s incidence remain uncertain. KS the only validated predictive model to gauge cancer patient´s risk for developing VTE. Methods: The aim of this study analyze and ambulatory patients (pts) with HGG receiving chemotherapy. We performed retrospective review 10 hospitals Cancer Thrombosis Working Group Spanish Society Medical Oncology (SEOM). A total 469 consecutive from January 2008 through December 2011 were included...
e15187 Background: VTE is a common complication in exocrine pancreatic cancer (EPC), however it´s true incidence remains uncertain. Khorana’s score the only validated predictive model to gauge patients’ risk for developing VTE. Methods: The aim of this study analyze symptomatic and incidental Khorana ambulatory patients (pts) with EPC receiving chemotherapy. We performed retrospective review nine hospitals Cancer&Thrombosis Working Group-Spanish Society Medical Oncology (SEOM). A total 571...